Statement: Personal opinion, for reference only!Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".Federal Reserve's December Outlook
The latest CPI data will be released tonight. The market expects the overall inflation rate to be 2.7%, 0.1 percentage point higher than that in October, and the core inflation rate is expected to be 3.3%, which is the same as that in October. Although the forecast data shows that the suppression of inflation by monetary policy is close to stagnation, it has dropped sharply compared with the previous peak of 9%. At present, the latest FEDWATCH data shows that the possibility of the Fed cutting interest rates next Tuesday is over 80%.A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!Quantum technology is one of the important directions of the next industrial revolution, and it is also one of the concepts that we have always suggested that everyone pay attention to. At present, it is in the initial stage, and the imagination space is huge. You can dig it well.
A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!Shanghai stock exchange recently releasedDezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.
Strategy guide 12-13
Strategy guide
12-13
Strategy guide
Strategy guide 12-13